BR112021025943A2 - Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos - Google Patents

Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos

Info

Publication number
BR112021025943A2
BR112021025943A2 BR112021025943A BR112021025943A BR112021025943A2 BR 112021025943 A2 BR112021025943 A2 BR 112021025943A2 BR 112021025943 A BR112021025943 A BR 112021025943A BR 112021025943 A BR112021025943 A BR 112021025943A BR 112021025943 A2 BR112021025943 A2 BR 112021025943A2
Authority
BR
Brazil
Prior art keywords
ovarian cancer
tsas
hgsc
specific antigens
innovative
Prior art date
Application number
BR112021025943A
Other languages
English (en)
Inventor
Claude Perrault
Pierre Thibault
Qingchuan Zhao
Sébastien Lemieux
Original Assignee
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal filed Critical Univ Montreal
Publication of BR112021025943A2 publication Critical patent/BR112021025943A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)

Abstract

antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos. o câncer de ovário, particularmente o câncer de ovário seroso de alto grau (hgsc), que é a principal causa de morte por malignidades ginecológicas no mundo, não se beneficiou significativamente do progresso recente na imunoterapia contra o câncer. embora a infiltração de hgsc por linfócitos se correlacione com a sobrevivência superior, a natureza dos antígenos que podem desencadear respostas imunes anti-hgsc é desconhecida. antígenos específicos de tumor (tsas) inovadores compartilhados por uma grande proporção de tumores ovarianos são descritos no presente documento. a maioria dos tsas (> 80%) aqui descritos deriva de sequências genômicas não mutadas expressas de forma aberrante, tais como sequências intrônicas e intergênicas, que não são expressas em tecidos normais. são descritos ácidos nucleicos, composições, células e vacinas derivadas desses tsas. o uso dos tsas, ácidos nucleicos, composições, células e vacinas para o tratamento de câncer de ovário também é descrito.
BR112021025943A 2019-06-25 2020-06-22 Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos BR112021025943A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962866089P 2019-06-25 2019-06-25
PCT/CA2020/050869 WO2020257922A1 (en) 2019-06-25 2020-06-22 Novel tumor-specific antigens for ovarian cancer and uses thereof

Publications (1)

Publication Number Publication Date
BR112021025943A2 true BR112021025943A2 (pt) 2022-02-08

Family

ID=74059840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025943A BR112021025943A2 (pt) 2019-06-25 2020-06-22 Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos

Country Status (12)

Country Link
US (1) US20220354937A1 (pt)
EP (1) EP3990483A4 (pt)
JP (1) JP2022539301A (pt)
KR (1) KR20220025808A (pt)
CN (1) CN114026117A (pt)
AU (1) AU2020301838A1 (pt)
BR (1) BR112021025943A2 (pt)
CA (1) CA3141898A1 (pt)
IL (1) IL288826A (pt)
MX (1) MX2022000046A (pt)
SG (1) SG11202113192QA (pt)
WO (1) WO2020257922A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3109716A1 (en) 2018-08-30 2020-03-05 Universite De Montreal Proteogenomic-based method for identifying tumor-specific antigens
AU2022331944A1 (en) * 2021-07-16 2024-02-01 Université de Montréal Novel tumor-specific antigens for cancer stem cells and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003111595A (ja) * 2001-06-25 2003-04-15 Kyogo Ito 腫瘍抗原
EP3777882A1 (en) * 2013-07-30 2021-02-17 BioNTech SE Tumor antigens for determining cancer therapy
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
MA47367B1 (fr) * 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
EP3990007A2 (en) * 2019-06-28 2022-05-04 The Francis Crick Institute Limited Novel cancer antigens and methods

Also Published As

Publication number Publication date
AU2020301838A1 (en) 2022-02-10
EP3990483A4 (en) 2024-02-21
CN114026117A (zh) 2022-02-08
US20220354937A1 (en) 2022-11-10
SG11202113192QA (en) 2021-12-30
KR20220025808A (ko) 2022-03-03
IL288826A (en) 2022-02-01
WO2020257922A1 (en) 2020-12-30
CA3141898A1 (en) 2020-12-30
JP2022539301A (ja) 2022-09-08
EP3990483A1 (en) 2022-05-04
MX2022000046A (es) 2022-02-24

Similar Documents

Publication Publication Date Title
BR112021025943A2 (pt) Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos
HRP20210766T1 (hr) Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
BR112019003866A2 (pt) adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite)
BR112018076027A2 (pt) método para modificar uma sequência-alvo no genoma de uma célula vegetal; método para editar uma sequência de nucleotídeos no genoma de uma célula vegetal; método para modificar simultaneamente múltiplas sequências-alvo no genoma de uma célula vegetal; método para modificar uma sequênciaalvo de dna no genoma de uma célula vegetal e modelo de modificação de polinucleotídeo
Na et al. Hypermethylation of growth arrest DNA-damage-inducible gene 45 in non-small cell lung cancer and its relationship with clinicopathologic features
WO2016036994A8 (en) Method of analysis allowing avoidance of surgery
MX2016014711A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).
MX2016005488A (es) Vector hsv oncolitico.
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
EA201690016A1 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
CL2017001336A1 (es) Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
NO20055708L (no) Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav
WO2018234506A3 (en) PERSONALIZED VACCINE
MX2019003546A (es) Virus oncoliticos optimizados y usos de los mismos.
Gokul et al. DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer
BR112022020376A2 (pt) Antígenos específicos de tumor para leucemia mieloide aguda (lma) e usos dos mesmos
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
UA113413C2 (uk) Пептид mphosph1 та вакцина, що його містить
Turhal et al. Prevalence of K-Ras mutations in hepatocellular carcinoma: AA Turkish Oncology Group pilot study
Carrozza et al. Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors
AR081065A1 (es) Peptidos ect2 (secuencia 2 de transformacion de la celula epitelial) y vacunas que los incluyen
MX2019013163A (es) Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma).